Trial for vaccine to prevent recurrence of Her2 + BC

Options
orange1
orange1 Member Posts: 930
edited June 2014 in HER2+ (Positive) Breast Cancer

Originally posted by TechtonicShift in the Male BC formum.

This trial is also open to women.

TectonicShift wrote:

Gentlemen, I want to make sure you all know about the AE37 vaccine trial that is going on right now. It's in phase II, and they are still recruiting participants. Early data is very promising. After a median followup of 22.3 months, about 10% fewer patients in the vaccine group have recurred as compared to the control (placebo) group. 

You must be at least one month and less than six months out from end of your standard of care treatment (end of rads or end of herceptin).

Here is the info: clinicaltrials.gov/ct2/show/NC...

There is also a site in Baltimore that is not listed on the trial sheet. PM me for info if you're interested in enrolling in Baltimore.

Here is are the latest results: www.asco.org/ASCOv2/Meetings/A...

This trial is for both men and women, so I encourage you to make a phone call if you can get to one of the trial sites every month for the next six months.  One of the sites is in Baltimore. PM me for details.

· Share on FacebookShare on Twitter

Comments

  • melissajnicholas
    melissajnicholas Member Posts: 2
    edited October 2012

    It might also be of value to know of the vaccine trial at the University of Pennsylvania under the direction of Dr. Czerniecki is in phase II attempting funding for Phase III to start vaccinating against reoccurence.  The great difference in AE37 as compared to this ICAIT (Immune Conditioning by Active Innate Transfer) therapy is that there has been NO Her2/neu patient that has recurred. Over 60 patients have been treated and the study goes back 8 years now.  

    The reason you don't hear as much about this vaccine is that the vaccine does not have anything that can be owned except the process.  There are no antigens to own.  This therapy uses dendritic cell breakthrough research, IL-12, and a naturally occuring bacteria to trick the patient's immune system into reacting to the cancer.  Again, none of this can be owned.  In layman's terms, it's like vitamins.  While the process is patented, you cannot own naturally occuring substances.  This makes Pharmacuetical companies uninterested except possibly to buy it and shelve it, never going to market.

    AE37 has a chemical that is not natural to our bodies.  While AE37 may be beneficial, I would argue if it's best path moving forward for the future of breast cancer treatment.  Patient's want the best possible chance to live.  As a survivor myself, I'll take 100% over 10%...it's obviously a no-brainer.  This treatment holds great promise for other cancers as well.  The great hurdle today is funds.  If you are interested in more information please visit www.penniesinaction.org.  It's going to take ALL of us to get this amazing treatment out to the market where we can save lots of grandmothers, mothers, daughters and sisters.  

    · Share on FacebookShare on Twitter
  • Lutienyc
    Lutienyc Member Posts: 9
    edited October 2012

    The ICAIT trial is on women with DCIS, a far cry from stage 2 and 3 AE37 volunteers. You cannot compare the results of the 2 trials.

    · Share on FacebookShare on Twitter
  • SpecialK
    SpecialK Member Posts: 16,486
    edited October 2012

    This is actually a trial that sorts by histological type - if you are A2- and sorted to the active vaccine arm you would get the AE37, but if you are A2+ you are sorted to the GP2 arm.  I am participating in this trial in Washington, D.C.

    orange - I can't get the ASCO link to work

    · Share on FacebookShare on Twitter
  • melissajnicholas
    melissajnicholas Member Posts: 2
    edited October 2012

    The ICAIT trial was rewritten by Dr. Czerniecki to include micro-invasions.  My point being, if women are still showing antibodies, some as far back as 8 years, this trial is worthy of our attention, especially against reoccurence.  www.penniesinaction.org

    · Share on FacebookShare on Twitter
  • Sydneybased
    Sydneybased Member Posts: 106
    edited October 2012

    Any discussion anywhere of AE37 being available to people who are more than 6 months out from treatment, but who haven't recurred?

    · Share on FacebookShare on Twitter

Categories